Table 1 Overall characteristics of all included studies
Author | Country | Participants (N) | Male (%) | Medical adherence tool | Condition (cvd) | Follow up (year) | NOS |
|---|---|---|---|---|---|---|---|
Esposti et al. 2011 [7] | Italy | 31,306 | 48 | PDC | Newly treated | 1.9 | 8/Low |
Gosmanova et al. 2014 [27] | US | 18,822 | 91.4 | PDC | Newly treated | 3.8 | 8/Low |
Ibrahim et al. 2023 [12] | US | 9,278 | 64.4 | VAS | Old | 3.8 | 7/Low |
Jung et al. 2023 a [20] | South Korea | 19,246 | 62.4 | MPR | Old | 8.4 | 8/Low |
Jung et al. 2023 b [21] | South Korea | 4,226 | 52.6 | PDC | Old | 8.2 | 8/Low |
Kim et al. 2016 [28] | South Korea | 33,728 | 46.6 | CMA | Newly treated | 5 | 8/Low |
Kim et al. 2021 [29] | South Korea | 20,836 | 47.4 | PDC | Newly treated | 9.6 | 8/Low |
Lee et al. 2019 [30] | South Korea | 1,651,564 | 52.5 | MPR | Newly treated | 10 | 8/Low |
Liu et al. 2014 [22] | China | 148,651 | 46 | PDC | Newly treated | 6.18 | 7/Low |
Shin et al. 2013 [18] | South Korea | 40,408 | 50.3 | MPR | Newly treated | 1 | 8/Low |
Tang et al. 2017 [23] | Canada | 2,199 | 45.4 | PDC | Newly treated | 4 | 7/Low |
Wong et al. 2013 [31] | Hong Kong | 218,047 | 45.1 | PDC | Newly treated | 5 | 7/Low |